Medtronic plc (NYSE:MDT) is one of the 8 Best Healthcare AI Stocks to Buy According to Analysts.
On April 26, 2026, Medtronic announced continued momentum for the Affera family of technologies for cardiac arrhythmia treatment, including promising data presented at the Heart Rhythm Society (HRS) Annual Meeting and the start of a new trial to evaluate a broader population of atrial fibrillation (Afib) patients. Results from the ongoing early feasibility study evaluating the Affera mapping and ablation system and the Sphere-9 catheter for treatment of recurrent sustained monomorphic ventricular tachycardia after a heart attack were presented as a late-breaking clinical trial. Patients treated at centers across the U.S. were followed for six months post-ablation. Results showed 65.5% of patients remaining free from VT recurrence at six months. The U.S. Food and Drug Administration granted Breakthrough Device Designation for the Sphere-9 catheter for the treatment of VT, providing an expedited regulatory pathway for the technology.
At HRS, a new sub-analysis from the Sphere-360 European study demonstrated positive results related to the durability of lesions in AFib procedures in patients with left common pulmonary veins. Results showed 100% lesion durability, highlighting consistency across patients with varied anatomies. Medtronic also announced the first patient enrollment in Conquer-AF, a prospective, multi-center, interventional, non-randomized study to characterize the safety and effectiveness of the Sphere-9 catheter in patients with recurrent paroxysmal or persistent AFib who have previously had an ablation procedure.
On April 23, 2026, Jefferies analyst Matthew Taylor lowered the firm’s price target on Medtronic (MDT) to $95 from $108 and kept a Hold rating on the shares. The firm updated its FY26 EPS outlook to reflect MiniMed (MMED) IPO timing and one-time expenses for MiniMed Flex. Jefferies added that Medtronic’s announced one-time $157M charge in Q4 related to the present value of future payments owed to Blackstone for the MiniMed Flex launch added to the EPS guide revision.
Medtronic plc (NYSE:MDT) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
While we acknowledge the risk and potential of MDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MDT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center